Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2017-08-07 Interim / Quarterly Rep…
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2017
2017-08-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions Item 2.02, which relates to 'Results of Operations and Financial Condition,' and references a press release attached as Exhibit 99.1. The document itself is short (2651 characters) and does not contain detailed financial statements or substantive financial data, but rather points to a press release for the results. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not contain the full earnings release or detailed financial report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-08-07 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is the announcement of the voluntary delisting of MannKind Corporation's common stock from the Tel Aviv Stock Exchange (TASE). The document states the delisting resolution by the board and the expected timeline for the delisting to become effective. There is no financial data, earnings information, or detailed report content. The document is an official notice of a stock exchange delisting event. Therefore, the appropriate classification is a Delisting Announcement (DLST). The document length is 3066 characters, which is consistent with a brief announcement rather than a full report.
2017-08-07 English
FORM 3 SUBMISSION
Director's Dealing
2017-07-25 English
FORM 3 SUBMISSION
Director's Dealing
2017-07-25 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The key content is the appointment of a new Chief Financial Officer and principal accounting officer, including details about his background and compensation. This corresponds to an announcement of changes in senior management. There are no financial statements or detailed financial data presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document fits the category of Board/Management Information (MANG) as it announces a management change.
2017-07-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.